27 March 2025 in American Journal of Gastroenterology
INTRODUCTION: Endoscopic retrograde appendicitis therapy (ERAT) is a new and noninvasive endoscopic technique originally developed by Liu in China for the management of acute appendicitis. Although its safety and efficacy have been extensively validated in adult populations, evidence regarding its use in pediatric patients remains scarce. The aim of this study was to evaluate the clinical outcomes of ERAT in pediatric appendicitis. METHODS: This retrospective study analyzed pediatric patients who underwent ERAT in our hospital between January 2019 and August 2022. Data collected included patient demographics, the success rate of ERAT, and the duration of hospital stay. In addition, recurrence rates were assessed during the follow-up to evaluate the safety and long-term efficacy of the procedure. RESULTS: A total of 73 patients were included in this study. Appendiceal intubation was successfully performed in 72 of 73 patients (98.63%). Among these patients, 72.22% of patients had appendiceal fecal stones or food residue, and the success rate of stone removal was 94.23%. Overall, the clinical success rate of the procedure was 91.78%. The median procedure time was 22 minutes (interquartile range 15–36.5), and the median postoperative hospital stay was 2 days (interquartile range 1–4). During the 1-year follow-up, 14.92% of the patients had recurrent appendicitis. DISCUSSION: ERAT seems to be a safe and effective alternative approach to treat appendicitis in pediatric patients, especially for obstructive appendicitis with appendicolith.
10 March 2026 in Microbial Biotechnology
Faecal microbiota transplantation (FMT) is highly effective for recurrent Clostridioides difficile infection but yields inconsistent benefits in chronic indications. As a crude whole‐microbiota transplant, FMT contains numerous undefined active components, complicating efforts to ensure treatment predictability and stability. Therefore, we propose Advance Microbiota Transplantation (AMT), a comprehensive, phase‐based hypothesis that employs an addition–subtraction strategy throughout the pre‐, peri‐ and post‐transplant stages. AMT comprises donor and recipient pre‐treatment, procedural optimisation and post‐transplant adjuvant interventions to mitigate donor variability, ecological resistance, procedural heterogeneity and unstable engraftment. Through a systematic synthesis of current evidence‐based FMT research, we explored how the addition–subtraction strategy can be operationalised to shape the AMT concept and define testable, phase‐specific levers, thereby providing a foundation for future clinical translation. In parallel, we appraised the reporting quality using the Preferred Reporting Items for Microbiotherapy (PRIM) and identified six persistently under‐reported items that limit the interpretability, comparability, and reproducibility of FMT research. This review aims to facilitate the integration of AMT into clinical practice.
1 September 2025 in International Journal for Vitamin and Nutrition Research
Background: Retinol-binding protein 4 (RBP4) is a vitamin A transport protein synthesized in the liver and also plays a crucial role in inflammation and immune regulation. Low serum vitamin A levels have been observed in both pediatric and adult patients with ulcerative colitis (UC). The association between serum vitamin A levels and serum RBP4 levels, as well as the underlying mechanism involved inimpaired vitamin A transport during inflammation in UC patients, has yet to been investigated. Methods: A validation cohort comprising 103 UC patients and 22 controls was analyzed. Serum RBP4 levels were measured using anenzyme-linked immunosorbent assay (ELISA), and correlations with vitamin A levels and disease severity wereassessed. A dextran sulfate sodium (DSS)-induced colitis mouse model was used to valuatehepatic RBP4 expression and inflammatory changes. Primary hepatocytes from C57BL/6 mice were exposed to inflammatory cytokines to assess the impact of these cytokines on RBP4 expression. Results: Serum vitamin A (p < 0.001) and RBP4 levels (p < 0.001) were significantly lower in UC patients compared to controls, exhibiting a pronounced decreasing trend as disease severity increased (vitamin A: p < 0.001; RBP4: p < 0.001), while vitamin A levels increased after effective treatment (p < 0.001). Hepatic RBP4 expression was reduced in the DSS-induced colitis model and negatively correlated with TNF-α, IL-6, and IL-17. Conclusions: Serum RBP4 levels are decreased in UC patients and negatively correlate with disease severity, possibly due to proinflammatory cytokine-induced suppression which might contribute to inflammation-driven vitamin A transport dysfunction.
7 July 2025 in American Journal of Gastroenterology